CureVac NV (CureVac NV) FCF Yield % : -52.21 (As of May. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, CureVac NV's Trailing 12-Month Free Cash Flow is $-347.81 Mil, and Market Cap is $695.35 Mil. Therefore, CureVac NV's FCF Yield % for today is -52.21%.

The historical rank and industry rank for CureVac NV's FCF Yield % or its related term are showing as below:

CVAC' s FCF Yield % Range Over the Past 10 Years
Min: -66.65 Med: -20.51 Max: -0.04
Current: -52.21

During the past 6 years, the highest FCF Yield % of CureVac NV was -0.04%. The lowest was -66.65%. And the median was -20.51%.

CVAC's FCF Yield % is ranked worse than
75.8% of 1554 companies
in the Biotechnology industry
Industry Median: -14.38 vs CVAC: -52.21

CureVac NV's FCF Margin % for the quarter that ended in Dec. 2023 was -257.07%.

CureVac NV FCF Yield % Historical Data

The historical data trend for CureVac NV's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV FCF Yield % Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

3.95

-15.15

-34.19

-37.36

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-25.14	-30.95	-14.55	-20.66	-26.84

Competitive Comparison of CureVac NV's FCF Yield %

For the Biotechnology subindustry, CureVac NV's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's FCF Yield % distribution charts can be found below:

* The bar in red indicates where CureVac NV's FCF Yield % falls into.

CureVac NV FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

CureVac NV's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-352.33	/	942.99369
	=	-37.36%

CureVac NV's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-63.265	*	4	/	942.99369
	=	-26.84%

CureVac NV FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

CureVac NV FCF Yield % Related Terms

Thank you for viewing the detailed overview of CureVac NV's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.